lantheus.comDiagnostic Medical Imaging Solutions | Lantheus

Contact Us Investors Media Media Resources SEC Filings Press Releases Email Alerts Contact Us Careers Join Our Team Current Opportunities The Candidate Process Life at Lantheus Taking Health to Heart Our Values Our Global Headquarters Employee Benefits Contact Us About Us COVID-19 See the Difference Leadership History Corporate Citizenship Grants Locations Products Overview Overview DEFINITY ® VIALMIX ® PINSYNC ® TechneLite ® Xenon-133 Calidose™ Dispenser System NEUROLITE ® Thallium-201 QUADRAMET ® Cardiolite ® Gallium-67 Fludeoxyglucose F 18 Injection Manufacturing & Supply Chain Customer Service Customer Service FAQs Standard Conditions of Sale Reimbursement Radiochemical Products Radiochemical Products Cobalt-57 Lead-203 Gallium-67 Xenon-133 Patent Information Pipeline New Product Development Flurpiridaz F 18 LMI 1195 (CNA) Art of Imaging Overview History of Innovation Medical Imaging 101 Echocardiography Nuclear Imaging Contact Us Investors Media Media Resources SEC Filings Press Releases Email Alerts Contact Us Careers Join Our Team Current Opportunities The Candidate Process Life at Lantheus Taking Health to Heart Our Values Our Global Headquarters Employee Benefits Contact Us Lantheus Completes Merger with Progenics June 22, 2020 – Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc., announces completion of merger with Progenics Pharmaceuticals, Inc. Learn More See the Difference Improved diagnostic information for better patient management Learn More Play Video See the Difference Brands you know; Quality you trust; Reliability you demand daily Learn More See the Difference Advancing the art of science and imaging Learn More News Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY® Read More Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results Read More Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time Read More   Coronavirus (COVID-19) Updates Providing you with important information regarding our response to the C0VID-19 pandemic. (updated 5/29/2020) View a recent Lantheus webinar: COVID-19: Clinical Experiences from the Front Line in NYC Read More News Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY® Read More Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results Read More Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time Read More   About Us At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care. Learn More Spotlight Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America. Learn More Pipeline We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging. Learn More Spotlight Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America. Learn More  Contact Us Privacy Policy Legal Notice Compliance Suppliers/Vendors © 2020 Lantheus Medical Imaging, Inc. All rights reserved. Intended for U.S. Residents only. 331 Treble Cove Road, N. Billerica, MA 01862 Telephone: 1-800-362-2668 Use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy . We use cookies to enhance your experience and to help us improve our website. To find out more about how we use cookies, read our Privacy Policy . By continuing to use this website, you agree to our use of cookies. Accept...